Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis. (June 2017)

• Record Type: Journal Article
• Authors: Blom, Kristin; Nygren, Peter; Larsson, Rolf; Andersson, Claes R.
• Other Names: Ho Dean guest-editor.; Zarrinpar Ali guest-editor.
• Is Part Of: SLAS technology. Volume 22:Number 3(2017)
• Page Start: 306
• Page End: 314
• Publication Date: 2017-06
• Subjects: tumor cell -- ex vivo -- chemotherapy -- individualized cancer therapy; Medical laboratory technology -- Periodicals; Laboratories -- Equipment and supplies -- Periodicals; Diagnosis, Laboratory -- Periodicals; 616.075
• DOI: 10.1177/2472630316686297
• Languages: English
• ISSNs: 2472-6303

Abstract

Current treatment strategies for chemotherapy of cancer patients were developed to benefit groups of patients with similar clinical characteristics. In practice, response is very heterogeneous between individual patients within these groups. Precision medicine can be viewed as the development toward a more fine-grained treatment stratification than what is currently in use. Cell-based drug sensitivity testing is one of several options for individualized cancer treatment available today, although it has not yet reached widespread clinical use. We present an up-to-date literature meta-analysis on the predictive value of ex vivo chemosensitivity assays for individualized cancer chemotherapy and discuss their current clinical value and possible future developments.